Monday, June 14, 2021

AUROPHARMA| Stock Price Outlook | New Stock Idea

Aurobindo Pharma Ltd.

CMP  998

➽  Aurobindo Pharma Limited engages in the research, development, manufacture, and sale of various pharmaceutical products in India. The company primarily offers oral solids, injectables, over the counter drugs, and dietary supplements, as well as active pharmaceutical ingredients and finished dosage forms for central nervous system, cardiovascular, anti-retroviral, anti-diabetics, anti-allergies, gastroenterology, antibiotics, dermatology, respiratory, and oncology, as well as specialty generic formulations.

➽ Key Stat

Promoters pledged 13.54% of shares in last quarter. Total pledge stands at 22.81% of promoter holdings

Promoters holding remains unchanged at 51.94% in Mar 2021 qtr

Mutual Funds have decreased holdings from 9.94% to 8.84% in Mar 2021 qtr

Number of MF schemes increased from 35 to 36 in Mar 2021 qtr.

FII/FPI have decreased holdings from 24.99% to 24.37% in Mar 2021 qtr

Number of FII/FPI investors decreased from 714 to 709 in Mar 2021 qtr

Institutional Investors have increased holdings from 37.6% to 37.61% in Mar 2021 qtr.

Financial Data Highlights

Market Cap59168.12
Book Value/ Share373.988
Enterprise Value12756.45
Revenue TTM24774.63
Gross Profit TTM14872.15
Revenue /Share TTM422.78

Key Profit & Loss Data

Net Inc5334.8588.45 %
Ops Income4278.039.45 %
Revenue24557.956.32 %
Ops Expense20279.927.89 %
PBT7343.6096.19 %
Gross Profit14655.4717.37 %
Div Paid-234.3133.43 %

BRNL | Potential Outperformer | Stock Price Outlook

 Technical & Price Outlook

auropharma ,

Bullish Momentum - Above Short, Medium and Long Term Moving Averages

Strong Performer: Stock with good financial performance alongside good to expensive valuation.

Long position can be made for the potential level of 1074  - 1108 in short term , 1234 in mid term.

IEX | Stock Analysis And Price Outlook

Thanks for your Precious Time.

Finvest Online
Telegram  :

Disclaimer- The information on this blog are based on my personal opinion and experience, it should not be considered professional financial investment advice and in no way it should be considered as a tip. We does not take any compensation of any kind whatsoever from any reader,user and company that are mention on this website.  Please remember that this is a blog, and you do not need to agree with anything I write.We are not SEBI registered financial advisor or analyst.

No comments:

Post a Comment